Costs and efficacy of a short-stay concept intervention in end phase Parkinson's disease. A comparison between 'regular' care and a short-stay concept.

Costs and efficacy of a short-stay concept intervention in end phase Parkinson's disease. A comparison between 'regular' care and a short-stay concept. - Costs and efficacy of a Parkinson's short-stay concept.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON34534

Enrollment

Registered

2010-12-02

Start date

2011-06-03

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

intervention 'within the Parkinsonpopulation

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: • Diagnosis of Parkinson's disease using the UK Brain Bank criteria • Patients who are no longer able to function at home by a combination of motor, cognition or behavioural problems (Hoehn and Yahr stadium III en IV) • Family member or caregiver is available to give adequate information about the functioning of the patient. • He patient is able to speak intelligible. • Written informed consent have to be present (patient or legal representative)

Exclusion criteria

Exclusion criteria: - Parkinsonism - MSA - PS - absence of comorbidity

Design outcomes

Primary

Measure	Time frame
Primary endpoint is the functional status of the Parkinson Patient. The functional status of the Parkinson's patient we measure using the ALDS. The question we can also translate into: • Is there a difference of score of the ALDS between the regular nursing homes and two nursing homes that perform the short-stay concept	—

Secondary

Measure	Time frame
Secondary endpoints: The motor status we measure using SCOPA-SPES • Is there a difference in the SCOPA-SPES between the regular nursing homes and two nursing homes that the short-stay concept execute. The Cognition is measured by the SCOPA -Cog. • Is there a difference in the SCOPA-Cog between the regular nursing homes and two nursing homes that the short-stay concept execute. The behavior of the patients we measure using the NPI. • Is there a difference in NPI between the regular nursing homes and two nursing homes that the short-stay embrace . The mood of the patients we measure using the BDI. • Is there a difference in FDI between the regular nursing homes and two nursing homes that use the short-stay concept . Quality of life we measure using the PDQL: • Is there a difference in PDQL between the regular nursing homes and two nursing homes that use the short-stay concept. The costs we measure using a questionnaire and so-called care / medicine cards: • Are there differences in the direct costs of admissions in regular nursing homes and the direct costs of the PSS approach and the continuation of treatment.	—

Measure

Time frame

Secondary endpoints: The motor status we measure using SCOPA-SPES • Is there a difference in the SCOPA-SPES between the regular nursing homes and two nursing homes that the short-stay concept execute. The Cognition is measured by the SCOPA -Cog. • Is there a difference in the SCOPA-Cog between the regular nursing homes and two nursing homes that the short-stay concept execute. The behavior of the patients we measure using the NPI. • Is there a difference in NPI between the regular nursing homes and two nursing homes that the short-stay embrace . The mood of the patients we measure using the BDI. • Is there a difference in FDI between the regular nursing homes and two nursing homes that use the short-stay concept . Quality of life we measure using the PDQL: • Is there a difference in PDQL between the regular nursing homes and two nursing homes that use the short-stay concept. The costs we measure using a questionnaire and so-called care / medicine cards: • Are there differences in the direct costs of admissions in regular nursing homes and the direct costs of the PSS approach and the continuation of treatment.

—

Countries

Netherlands

Outcome results